JP2019516410A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516410A5 JP2019516410A5 JP2019513483A JP2019513483A JP2019516410A5 JP 2019516410 A5 JP2019516410 A5 JP 2019516410A5 JP 2019513483 A JP2019513483 A JP 2019513483A JP 2019513483 A JP2019513483 A JP 2019513483A JP 2019516410 A5 JP2019516410 A5 JP 2019516410A5
- Authority
- JP
- Japan
- Prior art keywords
- segment
- pitindevirus
- pitin
- utr
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 claims description 118
- 239000000427 antigen Substances 0.000 claims description 59
- 102000036639 antigens Human genes 0.000 claims description 59
- 108091007433 antigens Proteins 0.000 claims description 59
- 241000700605 Viruses Species 0.000 claims description 48
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 40
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 38
- 108090000623 proteins and genes Proteins 0.000 claims description 32
- 206010028980 Neoplasm Diseases 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 29
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 claims description 21
- 108700026244 Open Reading Frames Proteins 0.000 claims description 21
- 208000015181 infectious disease Diseases 0.000 claims description 18
- 230000002458 infectious effect Effects 0.000 claims description 18
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 239000002299 complementary DNA Substances 0.000 claims description 14
- 230000003612 virological effect Effects 0.000 claims description 10
- 230000035897 transcription Effects 0.000 claims description 9
- 238000013518 transcription Methods 0.000 claims description 9
- 241000701022 Cytomegalovirus Species 0.000 claims description 6
- 241000711549 Hepacivirus C Species 0.000 claims description 6
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 6
- 102000017143 RNA Polymerase I Human genes 0.000 claims description 6
- 108010013845 RNA Polymerase I Proteins 0.000 claims description 6
- 102000009572 RNA Polymerase II Human genes 0.000 claims description 6
- 108010009460 RNA Polymerase II Proteins 0.000 claims description 6
- 239000013566 allergen Substances 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 5
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 5
- 230000002457 bidirectional effect Effects 0.000 claims description 5
- 108091006047 fluorescent proteins Proteins 0.000 claims description 5
- 102000034287 fluorescent proteins Human genes 0.000 claims description 5
- 108020004635 Complementary DNA Proteins 0.000 claims description 4
- 108020004414 DNA Proteins 0.000 claims description 4
- 108010086140 Interferon alpha-beta Receptor Proteins 0.000 claims description 4
- 102000007438 Interferon alpha-beta Receptor Human genes 0.000 claims description 4
- 241000699670 Mus sp. Species 0.000 claims description 4
- 208000037581 Persistent Infection Diseases 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000006798 recombination Effects 0.000 claims description 4
- 238000005215 recombination Methods 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 4
- 230000002238 attenuated effect Effects 0.000 claims description 3
- 102000003886 Glycoproteins Human genes 0.000 claims description 2
- 108090000288 Glycoproteins Proteins 0.000 claims description 2
- 108060003393 Granulin Proteins 0.000 claims description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims description 2
- 108060004795 Methyltransferase Proteins 0.000 claims description 2
- 102000007999 Nuclear Proteins Human genes 0.000 claims description 2
- 108010089610 Nuclear Proteins Proteins 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 102100039793 E3 ubiquitin-protein ligase RAG1 Human genes 0.000 claims 4
- 101000744443 Homo sapiens E3 ubiquitin-protein ligase RAG1 Proteins 0.000 claims 4
- 241000700721 Hepatitis B virus Species 0.000 claims 3
- 241001631646 Papillomaviridae Species 0.000 claims 3
- 108010054267 Interferon Receptors Proteins 0.000 claims 2
- 102000001617 Interferon Receptors Human genes 0.000 claims 2
- 230000001629 suppression Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 102000001183 RAG-1 Human genes 0.000 description 2
- 108060006897 RAG1 Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 108010054624 red fluorescent protein Proteins 0.000 description 2
- 108010077753 type II interferon receptor Proteins 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022161464A JP7547433B2 (ja) | 2016-05-18 | 2022-10-06 | ワクチンベクターとしての三セグメントピチンデウイルス |
| JP2024146333A JP2024170461A (ja) | 2016-05-18 | 2024-08-28 | ワクチンベクターとしての三セグメントピチンデウイルス |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662338400P | 2016-05-18 | 2016-05-18 | |
| US62/338,400 | 2016-05-18 | ||
| PCT/EP2017/061865 WO2017198726A1 (en) | 2016-05-18 | 2017-05-17 | Tri-segmented pichinde viruses as vaccine vectors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022161464A Division JP7547433B2 (ja) | 2016-05-18 | 2022-10-06 | ワクチンベクターとしての三セグメントピチンデウイルス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019516410A JP2019516410A (ja) | 2019-06-20 |
| JP2019516410A5 true JP2019516410A5 (enExample) | 2020-07-02 |
| JP7254018B2 JP7254018B2 (ja) | 2023-04-07 |
Family
ID=58800799
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019513483A Active JP7254018B2 (ja) | 2016-05-18 | 2017-05-17 | ワクチンベクターとしての三セグメントピチンデウイルス |
| JP2022161464A Active JP7547433B2 (ja) | 2016-05-18 | 2022-10-06 | ワクチンベクターとしての三セグメントピチンデウイルス |
| JP2024146333A Pending JP2024170461A (ja) | 2016-05-18 | 2024-08-28 | ワクチンベクターとしての三セグメントピチンデウイルス |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022161464A Active JP7547433B2 (ja) | 2016-05-18 | 2022-10-06 | ワクチンベクターとしての三セグメントピチンデウイルス |
| JP2024146333A Pending JP2024170461A (ja) | 2016-05-18 | 2024-08-28 | ワクチンベクターとしての三セグメントピチンデウイルス |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20190135875A1 (enExample) |
| EP (1) | EP3458593A1 (enExample) |
| JP (3) | JP7254018B2 (enExample) |
| KR (2) | KR20240095333A (enExample) |
| CN (2) | CN109804074B (enExample) |
| AU (2) | AU2017266738B2 (enExample) |
| BR (1) | BR112018073794A2 (enExample) |
| CA (1) | CA3023599A1 (enExample) |
| EA (1) | EA201892648A1 (enExample) |
| IL (2) | IL314272A (enExample) |
| MX (2) | MX2018013956A (enExample) |
| NZ (1) | NZ788311A (enExample) |
| SG (1) | SG11201810048VA (enExample) |
| WO (1) | WO2017198726A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2604695T3 (pl) | 2007-12-27 | 2023-04-11 | Universität Zürich | Cząstka arenawirusa z defektem replikacji |
| DK3077519T3 (en) | 2013-12-03 | 2021-06-14 | Hookipa Biotech Gmbh | Cmv-vacciner |
| HUE051390T2 (hu) | 2014-11-13 | 2021-03-01 | Univ Geneve | Háromszegmensû arenavírusok mint vakcinavektorok |
| HK1246183A1 (zh) | 2015-06-10 | 2018-09-07 | Hookipa Biotech Gmbh | Hpv疫苗 |
| CN115948467A (zh) | 2015-11-04 | 2023-04-11 | 霍欧奇帕生物科技有限公司 | 针对乙型肝炎病毒的疫苗 |
| CA3003548A1 (en) | 2015-11-12 | 2017-05-18 | Hookipa Biotech Ag | Arenavirus particles as cancer vaccines |
| AU2018247958A1 (en) * | 2017-04-07 | 2019-10-10 | Hookipa Biotech Gmbh | Arenavirus particles to treat solid tumors |
| WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| MX2021015452A (es) | 2019-06-25 | 2022-02-11 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso. |
| CA3145791A1 (en) | 2019-07-16 | 2021-01-21 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
| KR20220074917A (ko) | 2019-09-30 | 2022-06-03 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 백신 및 hbv를 치료하는 방법 |
| US20220380805A1 (en) | 2019-11-07 | 2022-12-01 | Universität Basel | Arenaviruses as vectors |
| DK4069729T3 (da) | 2019-12-06 | 2025-04-07 | Prec Biosciences Inc | Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet |
| JP7711068B2 (ja) | 2019-12-24 | 2025-07-22 | カルナバイオサイエンス株式会社 | ジアシルグリセロールキナーゼ調節化合物 |
| AR121620A1 (es) | 2020-03-20 | 2022-06-22 | Gilead Sciences Inc | Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos |
| BR112022024404A2 (pt) | 2020-05-29 | 2023-02-07 | Hookipa Biotech Gmbh | Método para tratar câncer, sequência de nucleotídeos, célula hospedeira, partícula de lcmv, partícula de picv, composição farmacêutica, partícula de arenavírus |
| KR20230131481A (ko) | 2021-01-14 | 2023-09-13 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 백신 및 이의 사용 방법 |
| BR112023019365A2 (pt) | 2021-03-23 | 2023-12-26 | Hookipa Biotech Gmbh | Segmento s de arenavírus, cdna, vetor de expressão de dna, célula hospedeira, partícula de arenavírus trissegmentada, método para gerar uma partícula de arenavírus trissegmentada, composição farmacêutica, método para tratar câncer de próstata e kit |
| US20240229073A1 (en) | 2021-05-13 | 2024-07-11 | Hookipa Biotech Gmbh | Arenaviruses as vectors |
| EP4337223A1 (en) | 2021-05-13 | 2024-03-20 | Gilead Sciences, Inc. | Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics |
| US20240285748A1 (en) * | 2021-06-21 | 2024-08-29 | Vaxxinova International B.V. | Veterinary viral vector |
| KR20240025616A (ko) | 2021-06-23 | 2024-02-27 | 길리애드 사이언시즈, 인코포레이티드 | 다이아실글리세롤 키나제 조절 화합물 |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| AU2022298639C1 (en) | 2021-06-23 | 2025-07-17 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP2024540385A (ja) * | 2021-11-08 | 2024-10-31 | ホオキパ バイオテック ジーエムビーエイチ | 変異型ｋｒａｓ、変異したがんドライバー遺伝子、または腫瘍関連抗原を発現する、がん免疫療法としての改変アレナウイルス粒子 |
| EP4475879A1 (en) | 2022-02-08 | 2024-12-18 | Hookipa Biotech GmbH | Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines |
| JP2025523043A (ja) | 2022-07-12 | 2025-07-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖ免疫原性ポリペプチド及びワクチン、並びにその使用 |
| WO2025191169A1 (en) | 2024-03-15 | 2025-09-18 | Hookipa Biotech Gmbh | Modified arenavirus particles expressing cancer testis antigens as cancer immunotherapies |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US8063063B2 (en) | 2006-03-23 | 2011-11-22 | Novartis Ag | Immunopotentiating compounds |
| WO2007109813A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
| PL2604695T3 (pl) * | 2007-12-27 | 2023-04-11 | Universität Zürich | Cząstka arenawirusa z defektem replikacji |
| ES2751423T3 (es) | 2013-03-15 | 2020-03-31 | Univ Geneve | Vacunas antimicobacterianas |
| CN103224999B (zh) * | 2013-04-25 | 2015-11-18 | 中华人民共和国大榭出入境检验检疫局 | 检测沙粒病毒科病毒的简并引物及rt-pcr检测方法 |
| BR112017005744B1 (pt) * | 2014-09-22 | 2023-11-28 | Regents Of The University Of Minnesota | "vírus pichinde geneticamente manipulado, método de fabricação e uso do mesmo, partícula viral infecciosa, composição, coleção de vetores, sistema de genética reversa e método de uso do mesmo" |
-
2017
- 2017-05-17 IL IL314272A patent/IL314272A/en unknown
- 2017-05-17 MX MX2018013956A patent/MX2018013956A/es unknown
- 2017-05-17 JP JP2019513483A patent/JP7254018B2/ja active Active
- 2017-05-17 CN CN201780044797.7A patent/CN109804074B/zh active Active
- 2017-05-17 IL IL262963A patent/IL262963B2/en unknown
- 2017-05-17 EP EP17726575.8A patent/EP3458593A1/en active Pending
- 2017-05-17 SG SG11201810048VA patent/SG11201810048VA/en unknown
- 2017-05-17 BR BR112018073794-1A patent/BR112018073794A2/pt active IP Right Grant
- 2017-05-17 WO PCT/EP2017/061865 patent/WO2017198726A1/en not_active Ceased
- 2017-05-17 US US16/302,086 patent/US20190135875A1/en not_active Abandoned
- 2017-05-17 KR KR1020247018106A patent/KR20240095333A/ko active Pending
- 2017-05-17 CA CA3023599A patent/CA3023599A1/en active Pending
- 2017-05-17 AU AU2017266738A patent/AU2017266738B2/en active Active
- 2017-05-17 NZ NZ788311A patent/NZ788311A/en unknown
- 2017-05-17 CN CN202311410316.3A patent/CN117486979A/zh active Pending
- 2017-05-17 KR KR1020187036105A patent/KR102671785B1/ko active Active
- 2017-05-17 EA EA201892648A patent/EA201892648A1/ru unknown
-
2018
- 2018-11-14 MX MX2024005757A patent/MX2024005757A/es unknown
-
2022
- 2022-05-23 US US17/751,319 patent/US20220289797A1/en active Pending
- 2022-10-06 JP JP2022161464A patent/JP7547433B2/ja active Active
-
2023
- 2023-12-18 AU AU2023285703A patent/AU2023285703A1/en active Pending
-
2024
- 2024-08-28 JP JP2024146333A patent/JP2024170461A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019516410A5 (enExample) | ||
| JP2023012463A5 (enExample) | ||
| JP2017535267A5 (enExample) | ||
| Bangari et al. | Development of nonhuman adenoviruses as vaccine vectors | |
| Afkhami et al. | Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens | |
| Lasaro et al. | New insights on adenovirus as vaccine vectors | |
| Sun et al. | The status and prospects of Epstein–Barr virus prophylactic vaccine development | |
| Tatsis et al. | Adenoviruses as vaccine vectors | |
| JP2021182922A5 (enExample) | ||
| WO2021164097A1 (zh) | 用于预防新型冠状病毒的生物制品 | |
| JP2018536433A5 (enExample) | ||
| JP2018518172A5 (enExample) | ||
| FI3371316T3 (fi) | Rokotteita hepatiitti b -virusta vastaan | |
| JP2017527557A5 (enExample) | ||
| JP2012507270A5 (enExample) | ||
| CN105861558A (zh) | 一种痘苗病毒穿梭载体及其制备方法和应用 | |
| Abdelaziz et al. | Development of a human cytomegalovirus (HCMV)-based therapeutic cancer vaccine uncovers a previously unsuspected viral block of MHC class I antigen presentation | |
| CN111218477B (zh) | 靶向感染哺乳动物细胞的禽4型腺病毒载体及其应用 | |
| CN101160055A (zh) | 慢病毒载体及其用途 | |
| JP5969044B2 (ja) | アデノウイルス生産新規細胞株及びその用途 | |
| Lv et al. | Efficient gene transfer into T lymphocytes by fiber-modified human adenovirus 5 | |
| CN114317606A (zh) | 靶向人nk细胞的腺病毒载体及其应用 | |
| CN103045544B (zh) | 预防西尼罗河病毒的重组假型杆状病毒Bac-G-prM/E及疫苗与应用 | |
| Kron et al. | miRNA-mediated silencing in hepatocytes can increase adaptive immune responses to adenovirus vector-delivered transgenic antigens | |
| CN116855547A (zh) | 基于hsv-1的疫苗和融瘤病毒载体的构建 |